You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles

Share

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles
(Your Name) has forwarded a page to you from Journal for ImmunoTherapy of Cancer
(Your Name) thought you would like to see this page from the Journal for ImmunoTherapy of Cancer web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.